ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
- PMID: 23137135
- DOI: 10.1111/1469-0691.12039
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients
Abstract
This part of the EFISG guidelines focuses on non-neutropenic adult patients. Only a few of the numerous recommendations can be summarized in the abstract. Prophylactic usage of fluconazole is supported in patients with recent abdominal surgery and recurrent gastrointestinal perforations or anastomotic leakages. Candida isolation from respiratory secretions alone should never prompt treatment. For the targeted initial treatment of candidaemia, echinocandins are strongly recommended while liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength. Treatment duration for candidaemia should be a minimum of 14 days after the end of candidaemia, which can be determined by one blood culture per day until negativity. Switching to oral treatment after 10 days of intravenous therapy has been safe in stable patients with susceptible Candida species. In candidaemia, removal of indwelling catheters is strongly recommended. If catheters cannot be removed, lipid-based amphotericin B or echinocandins should be preferred over azoles. Transoesophageal echocardiography and fundoscopy should be performed to detect organ involvement. Native valve endocarditis requires surgery within a week, while in prosthetic valve endocarditis, earlier surgery may be beneficial. The antifungal regimen of choice is liposomal amphotericin B +/- flucytosine. In ocular candidiasis, liposomal amphotericin B +/- flucytosine is recommended when the susceptibility of the isolate is unknown, and in susceptible isolates, fluconazole and voriconazole are alternatives. Amphotericin B deoxycholate is not recommended for any indication due to severe side effects.
© 2012 The Authors. Clinical Microbiology and Infection © 2012 European Society of Clinical Microbiology and Infectious Diseases.
Similar articles
-
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.Lancet. 2005 Oct 22-28;366(9495):1435-42. doi: 10.1016/S0140-6736(05)67490-9. Lancet. 2005. PMID: 16243088 Clinical Trial.
-
Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines.Infez Med. 2014 Jun;22(2):107-11. Infez Med. 2014. PMID: 24955796 Review.
-
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts.Intensive Care Med. 2013 Dec;39(12):2092-106. doi: 10.1007/s00134-013-3109-3. Epub 2013 Oct 9. Intensive Care Med. 2013. PMID: 24105327
-
Clinical aspects of invasive candidiasis: endocarditis and other localized infections.Drugs. 2009;69 Suppl 1:39-43. doi: 10.2165/11315610-000000000-00000. Drugs. 2009. PMID: 19877733 Review.
-
[INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].Akush Ginekol (Sofiia). 2016;55(4):20-29. Akush Ginekol (Sofiia). 2016. PMID: 29370489 Bulgarian.
Cited by
-
Outbreak of candidemia caused by fluconazole resistant Candida parapsilosis strains in an intensive care unit.BMC Infect Dis. 2016 Aug 20;16(1):433. doi: 10.1186/s12879-016-1767-9. BMC Infect Dis. 2016. PMID: 27544427 Free PMC article.
-
Recurrent candida prosthetic endocarditis over fifteen years managed with medical therapy and four valvular surgeries: a case report and review of literature.J Cardiothorac Surg. 2015 Jul 30;10:105. doi: 10.1186/s13019-015-0309-7. J Cardiothorac Surg. 2015. PMID: 26223448 Free PMC article. Review.
-
Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis.Antimicrob Agents Chemother. 2013 Apr;57(4):1672-6. doi: 10.1128/AAC.02139-12. Epub 2013 Jan 18. Antimicrob Agents Chemother. 2013. PMID: 23335738 Free PMC article. Clinical Trial.
-
Intra- and Interlaboratory Agreement in Assessing the In Vitro Activity of Micafungin against Common and Rare Candida Species with the EUCAST, CLSI, and Etest Methods.Antimicrob Agents Chemother. 2016 Sep 23;60(10):6173-8. doi: 10.1128/AAC.01027-16. Print 2016 Oct. Antimicrob Agents Chemother. 2016. PMID: 27480850 Free PMC article.
-
Heteroresistance to Fluconazole Is a Continuously Distributed Phenotype among Candida glabrata Clinical Strains Associated with In Vivo Persistence.mBio. 2016 Aug 2;7(4):e00655-16. doi: 10.1128/mBio.00655-16. mBio. 2016. PMID: 27486188 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical